Alkermes (ALKS) Profit After Tax (2010 - 2026)
Alkermes' (ALKS) quarterly Profit After Tax came in at -$67.3 million in Q1 2026, down 399.54% year-on-year from $22.5 million in Q1 2025, and down 239.31% on a QoQ basis from $48.3 million in Q4 2025.
Alkermes (ALKS) Profit After Tax (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Profit After Tax data on file, last reported at -$67.3 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 399.54% year-over-year to -$67.3 million in Q1 2026; TTM through Mar 2026 was $151.2 million, a 57.13% decrease from a year earlier, with the FY2025 full-year figure at $241.5 million, down 34.2% from the prior year.
- Profit After Tax for Q1 2026 stood at -$67.3 million, down from $48.3 million in the prior quarter.
- Over the last five years, Profit After Tax for ALKS reached as high as $237.1 million in Q2 2023 and fell as low as -$67.3 million in Q1 2026.
- Historically, Profit After Tax has averaged $43.5 million across 5 years, with a median of $48.3 million in 2025.
- Across the five-year window, Profit After Tax tumbled 3336.43% in 2022 and surged 886.65% in 2023, its largest moves.
- Year by year, Profit After Tax stood at -$28.3 million in 2022, then soared by 509.65% to $115.7 million in 2023, then rose by 26.58% to $146.5 million in 2024, then plunged by 67.03% to $48.3 million in 2025, then tumbled by 239.31% to -$67.3 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$67.3 million in Q1 2026, $48.3 million in Q4 2025, and $83.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -67.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.29 Mn |
| Dec 31, 2025 | 48.30 Mn |
| Sep 30, 2025 | 83.10 Mn |
| Jun 30, 2025 | 87.10 Mn |
| Mar 31, 2025 | 22.46 Mn |
| Dec 31, 2024 | 146.50 Mn |
| Sep 30, 2024 | 92.38 Mn |
| Jun 30, 2024 | 91.36 Mn |
| Mar 31, 2024 | 36.83 Mn |
| Dec 31, 2023 | 115.74 Mn |
| Sep 30, 2023 | 49.12 Mn |
| Jun 30, 2023 | 237.07 Mn |
| Mar 31, 2023 | -41.85 Mn |
| Dec 31, 2022 | -28.25 Mn |
| Sep 30, 2022 | -66.32 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 873,000.00 |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |